2023-27 Income statement and product revenue figures are as at 25/01/2024
£m (unless stated) | 2023 | 2024 | 2025 | 2026 | 2027 | 2023-27 n= |
---|---|---|---|---|---|---|
Turnover - Vaccines ex pandemic solutions | 9,573 | 10,453 | 11,420 | 12,248 | 12,812 | 14 |
Turnover - Specialty ex pandemic solutions | 9,981 | 10,927 | 11,765 | 12,563 | 13,194 | 14 |
Turnover - General Medicines | 10,195 | 9,619 | 9,559 | 9,510 | 9,242 | 14 |
Turnover - GSK excluding pandemic solutions | 29,749 | 30,999 | 32,745 | 34,321 | 35,248 | 14 |
Turnover - pandemic solutions | 175 | 2 | 2 | 1 | 1 | 14 |
Turnover - GSK | 29,924 | 31,001 | 32,747 | 34,322 | 35,249 | 14 |
Cost of sales | (7,617) | (7,740) | (8,089) | (8,429) | (8,633) | 14 |
Selling, general and administration | (8,946) | (9,091) | (9,339) | (9,598) | (9,739) | 14 |
Research and Development | (5,509) | (5,678) | (5,916) | (6,138) | (6,291) | 14 |
Royalty income | 900 | 492 | 552 | 591 | 543 | 14 |
Operating profit | 8,752 | 8,983 | 9,954 | 10,749 | 11,128 | 14 |
Net finance costs | (668) | (626) | (582) | (547) | (495) | 14 |
Associates | (2) | (1) | (1) | (1) | (1) | 14 |
Profit before tax | 8,082 | 8,356 | 9,372 | 10,201 | 10,632 | 14 |
Taxation | (1,237) | (1,433) | (1,622) | (1,775) | (1,860) | 14 |
Tax Rate | 15.3% | 17.1% | 17.3% | 17.4% | 17.5% | 14 |
Profit after tax | 6,845 | 6,923 | 7,749 | 8,426 | 8,772 | 14 |
Minority interests | (582) | (632) | (665) | (693) | (712) | 14 |
Profit attributable to shareholders | 6,263 | 6,291 | 7,085 | 7,732 | 8,061 | 14 |
WANS (m) | 4,052 | 4,072 | 4,091 | 4,107 | 4,114 | 14 |
Earnings per share (p) | 154.6 | 154.5 | 173.2 | 188.3 | 196.0 | 14 |
Dividend per share (p) | 56.4 | 58.7 | 61.0 | 63.2 | 65.0 | 13 |
Free Cash Flow | 4,236 | 4,952 | 5,843 | 6,445 | 6,745 | 11 |
Net Debt | (14,169) | (11,675) | (8,357) | (4,533) | (1,323) | 11 |
USD / GBP | 1.24 | 1.27 | 1.27 | 1.27 | 1.27 | 14 |
EUR / GBP | 1.15 | 1.16 | 1.16 | 1.16 | 1.16 | 13 |
JPY / GBP | 174 | 181 | 181 | 181 | 181 | 10 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research
Turnover £m | 2023 | 2024 | 2025 | 2026 | 2027 | 2023-2027 n= |
---|---|---|---|---|---|---|
Shingrix | 3,413 | 3,931 | 4,398 | 4,775 | 4,908 | 14 |
Arexvy | 1,093 | 1,454 | 1,865 | 2,200 | 2,482 | 14 |
Bexsero | 861 | 889 | 907 | 913 | 917 | 14 |
Menveo | 381 | 389 | 392 | 391 | 391 | 14 |
Other Meningitis | 22 | 22 | 22 | 22 | 22 | 8 |
Meningitis | 1,264 | 1,300 | 1,321 | 1,326 | 1,330 | 14 |
Fluarix/Flulaval | 545 | 517 | 510 | 506 | 504 | 14 |
Boostrix | 607 | 611 | 621 | 629 | 638 | 14 |
Cervarix | 140 | 137 | 137 | 137 | 136 | 13 |
Hepatitis | 624 | 648 | 670 | 684 | 695 | 14 |
Infanrix, Pediarix | 540 | 528 | 527 | 526 | 526 | 14 |
Rotarix | 613 | 606 | 615 | 621 | 628 | 14 |
Synflorix | 293 | 268 | 252 | 240 | 233 | 14 |
Established Vaccines | 3,258 | 3,233 | 3,250 | 3,259 | 3,275 | 14 |
Other Vaccines pipeline | - | 19 | 76 | 182 | 314 | 14 |
Vaccines ex pandemic solutions | 9,573 | 10,453 | 11,420 | 12,248 | 12,812 | 14 |
Pandemic solutions | 144 | 1 | 0 | 0 | 0 | 14 |
Vaccines | 9,717 | 10,454 | 11,421 | 12,248 | 12,812 | 14 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research
Turnover £m | 2023 | 2024 | 2025 | 2026 | 2027 | 2023-2027 n= |
---|---|---|---|---|---|---|
Tivicay | 1,358 | 1,208 | 1,074 | 975 | 883 | 13 |
Triumeq | 1,510 | 1,270 | 1,089 | 942 | 822 | 13 |
Juluca | 671 | 685 | 684 | 687 | 685 | 14 |
Dovato | 1,802 | 2,119 | 2,328 | 2,484 | 2,572 | 14 |
Dolutegravir based regimens | 5,341 | 5,281 | 5,175 | 5,088 | 4,961 | 14 |
Cabenuva | 681 | 989 | 1,258 | 1,494 | 1,676 | 14 |
Apretude | 148 | 298 | 461 | 598 | 702 | 14 |
Cabotegravir +/- rilpivirine | 829 | 1,287 | 1,719 | 2,092 | 2,378 | 14 |
Rukobia | 115 | 139 | 155 | 169 | 180 | 14 |
Other HIV (including pipeline) | 62 | 53 | 48 | 55 | 90 | n/a |
HIV | 6,347 | 6,761 | 7,098 | 7,404 | 7,609 | 14 |
Benlysta | 1,323 | 1,454 | 1,499 | 1,498 | 1,437 | 14 |
Nucala | 1,617 | 1,746 | 1,838 | 1,855 | 1,813 | 14 |
Zejula | 481 | 523 | 573 | 631 | 677 | 14 |
Blenrep | 40 | 35 | 44 | 55 | 65 | 14 |
Jemperli | 125 | 216 | 297 | 359 | 401 | 14 |
Ojjaara | 23 | 141 | 280 | 419 | 539 | 14 |
Other Oncology (including pipeline) | 0 | 1 | 10 | 33 | 54 | n/a |
Oncology | 669 | 915 | 1,204 | 1,497 | 1,735 | 14 |
camlipixant | - | - | 7 | 46 | 118 | 9 |
daprodustat | 7 | 42 | 68 | 88 | 104 | 12 |
depemokimab | - | - | 42 | 165 | 318 | 12 |
Specialty Medicines ex pandemic solutions | 9,981 | 10,927 | 11,765 | 12,563 | 13,194 | 14 |
Xevudy | 31 | 1 | 1 | 1 | 1 | 14 |
Specialty Medicines | 10,012 | 10,928 | 11,766 | 12,564 | 13,195 | 14 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research
Turnover £m | 2023 | 2024 | 2025 | 2026 | 2027 | 2023-2027 n= |
---|---|---|---|---|---|---|
Anoro | 536 | 527 | 526 | 523 | 512 | 14 |
Arnuity | 40 | 39 | 39 | 38 | 38 | 13 |
Avamys/Veramyst | 315 | 285 | 271 | 262 | 254 | 13 |
Flixotide/Flovent | 476 | 337 | 317 | 298 | 281 | 14 |
Incruse | 169 | 164 | 163 | 162 | 162 | 14 |
Relvar/Breo | 1,058 | 1,013 | 1,003 | 992 | 937 | 14 |
Seretide/Advair | 1,133 | 912 | 830 | 762 | 703 | 14 |
Trelegy | 2,159 | 2,430 | 2,650 | 2,816 | 2,800 | 14 |
Ventolin | 741 | 675 | 643 | 616 | 589 | 14 |
Other respiratory | 135 | 155 | 147 | 143 | 129 | 14 |
Respiratory | 6,760 | 6,536 | 6,588 | 6,613 | 6,404 | 14 |
Other General Medicines | 3,435 | 3,082 | 2,971 | 2,897 | 2,838 | 14 |
General Medicines | 10,195 | 9,619 | 9,559 | 9,510 | 9,242 | 14 |
The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Morgan Stanley, Redburn, UBS, Wolfe Research